Scripps Research scientists move forward with work to study opioid alternatives

Scripps Research discovery finds that restoring the naturally occurring compound erucamide in the eye stabilized tissue in preclinical models of retinal degeneration.

Family of compounds known as 1,2,3,5-tetrazines could have wide application in making new pharmaceuticals, chemical and biological probes, and other products.

Discoveries from Boger’s lab have led to unique strategies and methods for making molecules, as well as durable antibiotics, novel ways to treat chronic pain, and an experimental cancer vaccine.

Scientists discovered a way to enhance the activity of an enzyme long suspected of playing a role in metabolism. In a study involving mice, the compound reversed signs of diabetes.

Dale Boger, PhD, the Richard and Alice Cramer Professor of Chemistry at Scripps Research, has been awarded the E.C. Taylor Senior Award by the International Society of Heterocyclic Chemistry.

Abide Therapeutics, Inc., a clinical-stage biopharmaceutical company founded by Scripps Research professors Benjamin Cravatt, PhD, and Dale Boger, PhD, will be acquired by the Danish pharmaceutical firm H. Lundbeck A/S (Lundbeck).

The findings suggest these vaccines could increase chances of recovery in cases where a drug therapy alone is not working.

Scientists at Scripps Research have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.